Shares of biotech company Regeneron (NASDAQ:REGN) fell 9.6% in the morning session after the company reported weak first-quarter 2025 results. Its revenue missed significantly, and its EPS fell ...

“Regeneron is an American success story, with over 80 percent of our workforce and assets in the U.S. and all of our FDA-approved medicines invented in our New York laboratories. Our innovative ...

A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...

Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...

Dec 16 - Regeneron Pharmaceuticals (REGN.O), opens new tab has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York ...

Regeneron Pharmaceuticals, Inc.'s stock has dropped 30% since July due to concerns around Eylea's declining market share in the face of competition from generics and Roche's Vabysmo. Dupixent's ...

Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 4.6% after a judge denied the company's motion for a preliminary injunction to block an Amgen (AMGN) biosimilar version of Regeneron's blockbuster ...

Regeneron is joining its pharma peers in the venture investing sector, committing up to $500 million over the next five years for its new private financing arm. The New York pharma unveiled ...

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has ...

Regeneron Pharmaceuticals has delivered market-beating results for shareholders over the prior 10 years. With competition heating up, however, the biotech may be entering a period of slowing ...

Regeneron Pharmaceuticals Inc. announced Thursday an agreement in which it will pay up to $1.1 billion plus royalties for Sanofi S.A.'s stake in the Regeneron-Sanofi collaboration on cancer ...

Amgen reported sales of $1.117 billion for Repatha last year, which represented a 26% increase from 2020. Meanwhile, Regeneron registered sales of Praluent at $170 million, a 13% increase from ...